Brought to you by 
Allergan buys aesthetics firm Kythera in $1.9bn takeover
01 Jun 2021
Executive Summary
Fresh off from changing its corporate name from Actavis, Allergan PLC bought publicly traded aesthetics company Kythera Biopharmaceuticals Inc. for $1.9bn, or $75 per share (a 34% premium)--$60 in cash and $15 in Allergan stock (approximately 1.3mm shares).
Deal Industry
- Biotechnology
- Pharmaceuticals
Deal Status
- Final
Deal Type
-
Acquisition
- Full Acquisition
- Includes Contract
- Payment Includes Cash for Equity
- Payment Includes Stock
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Allergan buys aesthetics firm Kythera in $1.9bn takeover
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice